Sepsis-Pipeline Review, H1 2015

Sepsis-Pipeline Review, H1 2015

  • Products Id :- GMDHC6245IDB
  • |
  • Pages: 194
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Sepsis-Pipeline Review, H1 2015


Global Markets Direct's, 'Sepsis-Pipeline Review, H1 2015', provides an overview of the Sepsis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Sepsis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sepsis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Sepsis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Sepsis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Sepsis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Sepsis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Sepsis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Sepsis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Sepsis Overview 9

Therapeutics Development 10

Pipeline Products for Sepsis-Overview 10

Pipeline Products for Sepsis-Comparative Analysis 11

Sepsis-Therapeutics under Development by Companies 12

Sepsis-Therapeutics under Investigation by Universities/Institutes 16

Sepsis-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Unknown Stage Products 20

Sepsis-Products under Development by Companies 21

Sepsis-Products under Investigation by Universities/Institutes 26

Sepsis-Companies Involved in Therapeutics Development 27

Adrenomed AG 27

Altor BioScience Corporation 28

Am-Pharma B.V. 29

Arch Biopartners, Inc. 30

Asahi Kasei Pharma Corp. 31

Baxter International Inc. 32

Biomedica Management Corporation 33

Chiesi Farmaceutici SpA 34

Chiome Bioscience, Inc. 35

Cilian AG 36

Cognosci, Inc. 37

Diomune S.L 38

Endacea, Inc. 39

Evec, Inc. 40

Huons Co., Ltd. 41

Immune Response BioPharma, Inc. 42

ImmunNovative Developments SL 43

InflaRx GmbH 44

Integrated BioTherapeutics, Inc. 45

ISU ABXIS Co.,Ltd. 46

Lead Discovery Center GmbH 47

MSM Protein Technologies, Inc. 48

Navigen Pharmaceuticals, Inc. 49

Novadiscovery SAS 50

Noxxon Pharma AG 51

Ocata Therapeutics, Inc. 52

OncoImmune, Inc. 53

Opsona Therapeutics Ltd. 54

ProThera Biologics, LLC. 55

Silence Therapeutics plc 56

Stemedica Cell Technologies, Inc. 57

Syntiron LLC 58

Takeda Pharmaceutical Company Limited 59

TiGenix NV 60

XImmune AB 61

Sepsis-Therapeutics Assessment 62

Assessment by Monotherapy Products 62

Assessment by Target 63

Assessment by Mechanism of Action 65

Assessment by Route of Administration 67

Assessment by Molecule Type 69

Drug Profiles 71

3K3A-APC-Drug Profile 71

AB-022-Drug Profile 73

AcPepA-Drug Profile 74

adrecizumab-Drug Profile 75

Alpha B Crystalline-Drug Profile 76

ALT-836-Drug Profile 77

AM/AMBP-1-Drug Profile 79

Anti-Semaphorin 3A Antibodies-Drug Profile 81

Aspidasept-Drug Profile 82

Atu-111-Drug Profile 83

BaxB-01-Drug Profile 84

BaxG-03-Drug Profile 85

BaxM-159-Drug Profile 86

BRL-44408-Drug Profile 87

BTZO-2-Drug Profile 88

CN-16-Drug Profile 89

COG-133-Drug Profile 90

Combpath-5.0-Drug Profile 92

Combpath-6.0-Drug Profile 93

Cx-611-Drug Profile 94

Drug for Sepsis-Drug Profile 96

Drugs for Sepsis-Drug Profile 97

Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders-Drug Profile 98

Drugs to Inhibit Sialidase for Sepsis-Drug Profile 99

Escherichia coli vaccine-Drug Profile 100

EV-007156-Drug Profile 101

Glyco-23-Drug Profile 102

HBN-1-Drug Profile 103

HBN-3-Drug Profile 104

HBN-4-Drug Profile 105

HU-003-Drug Profile 106

IFX-1-Drug Profile 107

ImmStem-Drug Profile 108

ImmuneSafe-Drug Profile 109

IND-005-Drug Profile 110

IND-006-Drug Profile 111

IR-999-Drug Profile 112

ISU-201-Drug Profile 113

Klebsiella pneumoniae vaccine-Drug Profile 114

L-97-1-Drug Profile 115

LB-1148-Drug Profile 117

LR-17-Drug Profile 118

M-33-Drug Profile 119

meropenem-Drug Profile 120

Mesenchymal Stem Cells-Drug Profile 121

Metablok-Drug Profile 123

Micselon-Drug Profile 124

Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders-Drug Profile 125

Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease-Drug Profile 126

Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease-Drug Profile 127

Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease-Drug Profile 128

MSM-236-Drug Profile 130

Nanotherapeutics-Drug Profile 131

NAV-838-Drug Profile 132

NOXD-19-Drug Profile 134

OPN-305-Drug Profile 135

Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke-Drug Profile 137

Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis-Drug Profile 138

Recombinant Enzyme for Sepsis-Drug Profile 139

Recombinant Human Alkaline Phosphatase-Drug Profile 140

Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation-Drug Profile 142

Recombinant Protein for Sepsis-Drug Profile 143

Recombinant Protein for Sepsis, Inflammatory bowel disease, Acute Kidney Injury, Acute radiation syndrome and Ischemic organ injury-Drug Profile 144

Slit2N-Drug Profile 145

Small Molecule for Immunology, CNS, Cardiovascular and Infectious Disease-Drug Profile 147

Small Molecule for Sepsis-Drug Profile 148

Small Molecule to Inhibit DDAH1 for Sepsis-Drug Profile 149

Small Molecules for Inflammatory Diseases and Sepsis-Drug Profile 150

Small Molecules to Inhibit LPS for Bacterial Sepsis-Drug Profile 151

Small Molecules to Inhibit NET Formation for Sepsis and SLE-Drug Profile 152

staphylococcus aureus (bivalent) vaccine-Drug Profile 153

Stem Cell Therapy for Autoimmune Diseases-Drug Profile 154

Synthetic Peptide to Inhibit TREM-1 for Cancer and Infectious Diseases-Drug Profile 155

Synthetic Peptides for Immunology and Infectious Diseases-Drug Profile 156

Synthetic Peptides for Inflammation and Infectious Disorders-Drug Profile 157

Synthetic Peptides for Sepsis, Bacterial and Fungal Infections-Drug Profile 158

Synthetic Peptides to Inhibit HSP90 for Oncology, Septic Shock, Inflammatory and Infectious Diseases-Drug Profile 159

Synthetic Peptides to Inhibit LPS for Bacterial and Viral Infections-Drug Profile 160

thrombomodulin alfa-Drug Profile 161

TRX-306-Drug Profile 163

vancomycin-Drug Profile 164

Yersinia pestis vaccine-Drug Profile 165

Sepsis-Recent Pipeline Updates 166

Sepsis-Dormant Projects 176

Sepsis-Discontinued Products 180

Sepsis-Product Development Milestones 182

Featured News & Press Releases 182

Appendix 187

Methodology 187

Coverage 187

Secondary Research 187

Primary Research 187

Expert Panel Validation 187

Contact Us 187

Disclaimer 188

List of Tables

Number of Products under Development for Sepsis, H1 2015 16

Number of Products under Development for Sepsis-Comparative Analysis, H1 2015 17

Number of Products under Development by Companies, H1 2015 18

Number of Products under Development by Companies, H1 2015 (Contd..1) 19

Number of Products under Development by Companies, H1 2015 (Contd..2) 20

Number of Products under Development by Companies, H1 2015 (Contd..3) 21

Number of Products under Investigation by Universities/Institutes, H1 2015 22

Comparative Analysis by Late Stage Development, H1 2015 23

Comparative Analysis by Clinical Stage Development, H1 2015 24

Comparative Analysis by Early Stage Development, H1 2015 25

Comparative Analysis by Unknown Stage Development, H1 2015 26

Products under Development by Companies, H1 2015 27

Products under Development by Companies, H1 2015 (Contd..1) 28

Products under Development by Companies, H1 2015 (Contd..2) 29

Products under Development by Companies, H1 2015 (Contd..3) 30

Products under Development by Companies, H1 2015 (Contd..4) 31

Products under Investigation by Universities/Institutes, H1 2015 32

Sepsis-Pipeline by Adrenomed AG, H1 2015 33

Sepsis-Pipeline by Altor BioScience Corporation, H1 2015 34

Sepsis-Pipeline by Am-Pharma B.V., H1 2015 35

Sepsis-Pipeline by Arch Biopartners, Inc., H1 2015 36

Sepsis-Pipeline by Asahi Kasei Pharma Corp., H1 2015 37

Sepsis-Pipeline by Baxter International Inc., H1 2015 38

Sepsis-Pipeline by Biomedica Management Corporation, H1 2015 39

Sepsis-Pipeline by Chiesi Farmaceutici SpA, H1 2015 40

Sepsis-Pipeline by Chiome Bioscience, Inc., H1 2015 41

Sepsis-Pipeline by Cilian AG, H1 2015 42

Sepsis-Pipeline by Cognosci, Inc., H1 2015 43

Sepsis-Pipeline by Diomune S.L, H1 2015 44

Sepsis-Pipeline by Endacea, Inc., H1 2015 45

Sepsis-Pipeline by Evec, Inc., H1 2015 46

Sepsis-Pipeline by Huons Co., Ltd., H1 2015 47

Sepsis-Pipeline by Immune Response BioPharma, Inc., H1 2015 48

Sepsis-Pipeline by ImmunNovative Developments SL, H1 2015 49

Sepsis-Pipeline by InflaRx GmbH, H1 2015 50

Sepsis-Pipeline by Integrated BioTherapeutics, Inc., H1 2015 51

Sepsis-Pipeline by ISU ABXIS Co.,Ltd., H1 2015 52

Sepsis-Pipeline by Lead Discovery Center GmbH, H1 2015 53

Sepsis-Pipeline by MSM Protein Technologies, Inc., H1 2015 54

Sepsis-Pipeline by Navigen Pharmaceuticals, Inc., H1 2015 55

Sepsis-Pipeline by Novadiscovery SAS, H1 2015 56

Sepsis-Pipeline by Noxxon Pharma AG, H1 2015 57

Sepsis-Pipeline by Ocata Therapeutics, Inc., H1 2015 58

Sepsis-Pipeline by OncoImmune, Inc., H1 2015 59

Sepsis-Pipeline by Opsona Therapeutics Ltd., H1 2015 60

Sepsis-Pipeline by ProThera Biologics, LLC., H1 2015 61

Sepsis-Pipeline by Silence Therapeutics plc, H1 2015 62

Sepsis-Pipeline by Stemedica Cell Technologies, Inc., H1 2015 63

Sepsis-Pipeline by Syntiron LLC, H1 2015 64

Sepsis-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 65

Sepsis-Pipeline by TiGenix NV, H1 2015 66

Sepsis-Pipeline by XImmune AB, H1 2015 67

Assessment by Monotherapy Products, H1 2015 68

Number of Products by Stage and Target, H1 2015 70

Number of Products by Stage and Mechanism of Action, H1 2015 72

Number of Products by Stage and Route of Administration, H1 2015 74

Number of Products by Stage and Molecule Type, H1 2015 76

Sepsis Therapeutics-Recent Pipeline Updates, H1 2015 172

Sepsis-Dormant Projects, H1 2015 182

Sepsis-Dormant Projects (Contd..1), H1 2015 183

Sepsis-Dormant Projects (Contd..2), H1 2015 184

Sepsis-Dormant Projects (Contd..3), H1 2015 185

Sepsis-Discontinued Products, H1 2015 186

Sepsis-Discontinued Products (Contd..1), H1 2015 187

List of Figures

Number of Products under Development for Sepsis, H1 2015 16

Number of Products under Development for Sepsis-Comparative Analysis, H1 2015 17

Number of Products under Development by Companies, H1 2015 18

Number of Products under Investigation by Universities/Institutes, H1 2015 22

Comparative Analysis by Clinical Stage Development, H1 2015 24

Comparative Analysis by Early Stage Products, H1 2015 25

Assessment by Monotherapy Products, H1 2015 68

Number of Products by Top 10 Targets, H1 2015 69

Number of Products by Stage and Top 10 Targets, H1 2015 69

Number of Products by Top 10 Mechanism of Actions, H1 2015 71

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 71

Number of Products by Top 10 Routes of Administration, H1 2015 73

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 74

Number of Products by Top 10 Molecule Types, H1 2015 75

Number of Products by Stage and Top 10 Molecule Types, H1 2015 76

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Adrenomed AG

Altor BioScience Corporation

Am-Pharma B.V.

Arch Biopartners, Inc.

Asahi Kasei Pharma Corp.

Baxter International Inc.

Biomedica Management Corporation

Chiesi Farmaceutici SpA

Chiome Bioscience, Inc.

Cilian AG

Cognosci, Inc.

Diomune S.L

Endacea, Inc.

Evec, Inc.

Huons Co., Ltd.

Immune Response BioPharma, Inc.

ImmunNovative Developments SL

InflaRx GmbH

Integrated BioTherapeutics, Inc.


Lead Discovery Center GmbH

MSM Protein Technologies, Inc.

Navigen Pharmaceuticals, Inc.

Novadiscovery SAS

Noxxon Pharma AG

Ocata Therapeutics, Inc.

OncoImmune, Inc.

Opsona Therapeutics Ltd.

ProThera Biologics, LLC.

Silence Therapeutics plc

Stemedica Cell Technologies, Inc.

Syntiron LLC

Takeda Pharmaceutical Company Limited

TiGenix NV

XImmune AB

Sepsis Therapeutic Products under Development, Key Players in Sepsis Therapeutics, Sepsis Pipeline Overview, Sepsis Pipeline, Sepsis Pipeline Assessment

select a license

Single User License
USD 2000 INR 135980
Site License
USD 4000 INR 271960
Corporate User License
USD 6000 INR 407940



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]